Skip to main content
letter
. 2020 Jun 4;106(3):886–890. doi: 10.3324/haematol.2020.249094

Figure 1.

Figure 1.

Outcome analysis. (A-D) Event-free survival and cumulative incidence of relapse at 5 years according to ZEB2mut status in patients with newly diagnosed B-other acute lymphocytic leukemia in the discovery cohort (A, B) and those from the validation cohort who were treated on the AIEOP-BFM ALL 2000 protocol (C,D). SE: standard error.